EPRX: Rega marang dodolan Eupraxia Pharmaceuticals

Logo korporat perusahaan Eupraxia Pharma (EPRX)

The prospects for Eupraxia Pharmaceuticals (EPRX) are based on the creation of a long-acting drug ecosystem via DiffuX, which is supported by historical P/S dynamics, where the current level is approximately 0.00. The company's revenues rely on bringing osteoarthritis therapies to market. Production cycles for injectable drugs are supported by certified CMO capacities, which are currently expanding to accommodate new trials.

Rasio rega marang pendapatan: eupraxiapharma.com (EPRX) kanggo 06.04.2024 - 06.04.2024

Rincian analitis perusahaan eupraxiapharma.com (EPRX)

Ringkesan analitik perusahaan:Eupraxia Pharma (EPRX)
Produk dadi Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals' development of innovative drug delivery systems with optimized logistics makes the P/S multiple a key tool for monitoring the business's market value. This indicator compares current market capitalization with annual revenue, allowing investors to determine the asset's degree of overheating and assess the efficiency of monetizing unique drug delivery technologies relative to market expectations.

Perusahaan pesaing

HLN (Haleon) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Kenvue Inc KVUE|Verona Pharma Corp - Rasio rega marang pendapatan|MENS: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Rasio rega marang pendapatan|Perrigo Company PLC - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan alvotech.com|Multiplikator P/S Liquidia Technologies|Rasio rega marang pendapatan Galapagos Genomics (GLPG)|ANIP: Rasio rega marang dodolan|Multiplikator P/S MNKD (MannKind Corp)|Koefisien rega marang pendapatan Amphastar (AMPH)|PCRX: Kapitalisasi marang pendapatan|SPRY - Multiplikator P/S|Theravance Biopharma, Inc. (TBPH) - Rasio rega marang pendapatan|AQST (Aquestive Therapeutics) - Rasio rega marang pendapatan|SCPH (scpharmaceuticals.com) - Multiplikator P/S|TECX: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Rasio kapitalisasi pasar marang pendapatan|BioHarvest Sciences - Kapitalisasi marang pendapatan|EXOZ: Rasio kapitalisasi marang pendapatan|ORMP - Rasio rega marang pendapatan|ENTX: Rasio rega marang pendapatan|HYFT: Multiplikator P/S|Kapitalisasi marang pendapatan ABVC BioPharma Inc|CPIX (Cumberland Corp) - Multiplikator P/S|Multiplikator P/S quantumbiopharma.com|Multiplikator P/S FGEN|Kapitalisasi marang pendapatan Telomir Pharmaceuticals, Inc. TELO|Multiplikator P/S RANI (Rani Therapeutics)|SNYR (Synergy CHC Corp) - Rasio rega marang dodolan|RLYB: Kapitalisasi marang pendapatan|lexariabioscience.com (LEXX) - Kapitalisasi marang pendapatan|Pulmatrix Inc (PULM) - Rasio rega marang pendapatan|PTHL: Kapitalisasi marang volume dodolan|APM (Aptorum Group Ltd) - Multiplikator P/S|Lyra Therapeutics Inc (LYRA) - Koefisien rega marang pendapatan|Multiplikator P/S IBO|Kapitalisasi marang volume dodolan TNFA|cbdMD, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan PRFX|Altamira Therapeutics Ltd. - Multiplikator P/S|LIPO: Rasio rega marang pendapatan|OPTN: Multiplikator P/S|Rasio rega marang dodolan PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - Multiplikator P/S|PTPI (Petros Pharmaceuticals Inc) - Kapitalisasi marang volume dodolan|Multiplikator P/S QLI|SLRN - Rega marang dodolan|Multiplikator P/S TFFP (TFF Pharmaceuticals, Inc)